Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Issues $5M Convertible Note to Ironridge

NEW YORK (GenomeWeb News) – Genetic Technologies said yesterday that it has issued a $5 million redeemable convertible note to Ironridge BioPharma, a division of institutional investor Ironridge Global IV, Ltd.

The Melbourne, Australia-based molecular diagnostics firm said that it as received A$5.6 million (US$5 million) from Ironridge in exchange for the note. The firm previously said that the notes issued to Ironridge would be convertible into new Nasdaq-traded American Depository Receipts at a fixed price of US$3.00 per ADR.

In Tuesday morning trade on the Nasdaq, Genetic Technologies' ADRs were trading up nearly 3 percent at US$1.59.

"The funds raised from the note, together with the net proceeds from the recently completed private placement and share purchase plan, adequately position the company with resources necessary to expand its US operations and continue the growth of its flagship test Brevagen," Genetic Technologies Chairman Mal Brandon said in a statement. "In addition, the funds will be used to complete studies that will add new ethnicities to increase the size of the available market and improve reimbursement performance."

Brevagen is the firm's flagship non-familial breast cancer risk assessment test.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.